Trials / Unknown
UnknownNCT03631147
The Effect of Rifaximin on Portal Vein Thrombosis
The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the efficacy of rifaximin in the treatment of portal vein thrombosis in cirrhotic patients
Detailed description
Portal vein thrombosis is not an uncommon complication in cirrhotic portal hypertension, which lead to a poor prognosis in endoscopic management of variceal bleeding. Evidence indicated that enoxaparin prevented PVT and liver decompensation via decreased rates of bacterial infections and lowered the potent inflammatory mediators such as interleukin-6. Rifaximin is a broad-spectrum antibiotic that exerts endotoxin-lowering and anti-inflammatory effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin | 400mg bid for 8 weeks |
Timeline
- Start date
- 2018-09-03
- Primary completion
- 2019-06-30
- Completion
- 2019-12-31
- First posted
- 2018-08-15
- Last updated
- 2018-08-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03631147. Inclusion in this directory is not an endorsement.